Benjamin Hohl, CFO, on July 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $316,780. Following the Form 4 filing with the SEC, Hohl has control over a total of 46,054 common shares of the company, with 46,054 shares held directly.
SEC Filing: